Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Lung Cancer. 2017 Mar 29;108:173–182. doi: 10.1016/j.lungcan.2017.03.017

Table 1.

Differences of demographic, clinical, and treatment characteristics of patients with stage III NSCLC by chemoradiation sequence.

Concurrent-alone Concurrent-consolidation Induction-Concurrent Sequential P P*
Characteristic n=792 n=896 n=140 n=115
Chemoradiation regimen
  Carboplatin-paclitaxel 595 654 99 75 <.0001 0.0005
  Carboplatin-docetaxel 48 100 21 17
  Carboplatin-gemcitabine <11 <11 <20 <20
  Carboplatin-etoposide 19 >22 <11 <11
  Cisplatin-etoposide 128 >99 <11 <11
Age
  Median 74 72 73 74 <.0001 <.0001
Gender
  Male 427 504 75 59 0.64 0.35
  Female 365 392 65 56
Race
  White 685 764 129 104 0.16 0.15
  Black 57 76 <11 <11
  Hispanic 28 20 <11 <11
  Other 22 36 <11 <11
Marital status
  Unmarried 324 315 53 35 0.03 0.003
  Married 456 549 >73 >66
  Unknown 12 32 <11 <11
Year of diagnosis
  2002 54 46 13 18 0.0009 0.18
  2003 58 85 11 18
  2004 82 113 21 13
  2005 99 115 17 17
  2006 94 124 19 <11
  2007 106 116 17 11
  2008 138 141 25 >9
  2009 161 156 17 12
Geographic region
  West 258 280 51 34 0.10 0.80
  Midwest 151 170 20 12
  South 212 235 36 29
  Northeast 171 211 33 40
Urban region
  Urban 701 793 128 >97 0.36 1.00
  Rural 91 103 12 <11
Educational attainment of area (≥4 years college)
  1st quartile 199 231 28 22 0.26 0.92
  2nd quartile 199 230 34 27
  3rd quartile 197 225 41 25
  4th quartile 197 210 37 41
Median income of area
  1st quartile 198 237 29 21 0.26 0.66
  2nd quartile 210 217 34 24
  3rd quartile 197 218 41 31
  4th quartile 187 224 36 39
Modified Charlson comorbidity
  0 511 563 98 66 0.69 0.85
  1 196 231 29 35
  2 51 65 <11 <11
  ≥3 34 37 <11 <11
Performance score proxy
  0 723 827 >121 >98 0.47 0.14
  1 42 52 <11 <11
  ≥2 27 17 <11 <11
COPD
  No 512 590 106 70 0.05 0.61
  Yes 280 306 34 45
Home oxygen use
  No 727 838 >122 103 0.26 0.19
  Yes 65 58 <11 12
Tumor size
  ≤2 cm 66 77 15 11 0.33 0.16
  2.1–3 cm 114 119 20 12
  3.1–5 cm 247 269 38 32
  5.1–7 cm 153 151 28 25
  ≥7 cm 75 121 22 11
  Unknown 137 159 17 24
Nodal status
  N0 115 107 16 11 0.14 0.02
  N1 37 >20 <11 <11
  N2 511 570 88 >69
  N3 117 180 >20 18
  Unknown 12 <11 <11 <11
Histology
  Adenocarcinoma 214 265 51 35 0.35 0.51
  Squamous cell 303 330 51 39
  Other 275 301 38 41
Diagnostic PET done
  No 425 503 93 89 <.0001 0.33
  Yes 367 393 47 26
Brain CT/MR done
  No 295 313 61 72 <.0001 0.33
  Yes 497 583 79 43
Invasive mediastinal imaging performed
  No 629 671 116 89 0.06 0.03
  Yes 163 225 24 26
Radiation type
  IMRT 110 97 17 15 0.29 0.06
  3D-CRT 682 799 123 100
Radiation facility type
  Freestanding center 198 206 32 36 0.12 0.48
  Hospital-based center 219 268 47 21
  Hospital-based NCI center 375 422 61 58
Area radiation oncologist density 179 222 36 22
  1st quartile 0.006 0.0009
  2nd quartile 180 162 27 22
  3rd quartile 164 177 35 34
  4th quartile 162 246 28 >17
  Unknown 107 89 14 <11
*

P value represents concurrent-alone versus concurrent-consolidation. Exact figures not specified in some cells to protect patient identity.